BIOGENERA SpA is in the process of finalizing the establishment of a new operating unit of the Company in Paris.
After a period of careful evaluation for the most appropriate choice, the final decision was made for the Paris Saclay Cancer Cluster (PSCC)(https://www.parissaclaycancercluster.org).
The Paris Saclay Cancer Cluster is located in Paris, in the Villejuif area, and is the first oncology cluster in France, recognized as an international excellence. The PSCC promotes collaboration among scientific, medical and industrial communities internationally, providing access to cutting-edge resources and treatments.
The establishment of the new business unit in Paris is also considered strategic in relation toBIOGENERA’s upcoming listing on the Paris Euronext exchange, which is expected within this year.
BIOGENERA’s presence at Paris Saclay Cancer Cluster: in the initial phase it will be related to office space, with limited number of people following BIOGENERA’s activities in Paris. At a later stage BIOGENERA will consider expanding the number of people and spaces (including workshops).
What can BIOGENERA offer the Paris Saclay Cancer Cluster?
Its new class of drugs (anti-gene oligonucleotides) identified and developed through the MyGenera platform for precision medicine by specifically blocking cancer genes. BIOGENERA will also offer opportunities to participate in clinical trials of the new anti-tumor drug BGA002 for the treatment of pediatric and adult MYCN-related cancers, and in preclinical and clinical studies of other new anti-tumor drugs already identified in development (such as drug BGA003 for the treatment of breast cancers and lymphomas with MYC tumor gene alterations).
What can the Paris Saclay Cancer Cluster offer to BIOGENERA?
The Paris Saclay Cancer Cluster offers the Opportunity to create networks and partnerships with Researchers and Clinicians from highly qualified Research Centers and Hospitals such as the Gustave Roussie (Europe’s largest oncology clinic) and the Marie Curie, with the University Paris Saclay, and with pharmaceutical companies in the area such as Sanofi, Ipsen, and Servier. BIOGENERA’s new operating unit in Paris joins the company’s existing Research and Development Center in Bologna, and will play a complementary role, expanding activities, creating new strategic partnerships of excellence.
